Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novartis Bets On Buybacks Due To Limited M&A Options

Unveils Another $15bn Share Repurchasing Program

Jul 18 2023

• By Kevin Grogan

Harry Kirsch — CFO Harry Kirsch • Source: Novartis

Related Content

Novartis Plumps For Share Buybacks Before Bolt-On M&A

Dec 16 2021

Patents And LOEs Poised To Be Hot Q2 Topics

Jul 13 2023

ANDA Sponsors Knock Out Key US Entresto Patent, Mylan Falls To Infringement

Jul 11 2023

Related Companies

Novartis AG

DTx Pharma

Additional Topics

M & A Sales & Earnings Intellectual Property Commercial Business Strategies BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.